Evangelia Sereti, MSc, PhD, discusses the next steps with the combination of NOV202 and olaparib in BRCA1/2-mutated prostate cancer.
Evangelia Sereti, MSc, PhD, a postdoctoral fellow at Urological Cancer, Malmö, Division of Translational Cancer Research, Lund University Cancer Centre, discusses the next steps with the combination of NOV202 and olaparib (Lynparza) in BRCA1/2-mutated prostate cancer.
Preclinical findings, which were presented during the 2021 EAU Congress, demonstrated promising anticancer effects with NOV202 in BRCA1/2-mutated prostate cancer xenografts. The agent also demonstrated synergistic effects when combined with the PARP inhibitor olaparib.
Building on these results, another study will evaluate the underlying mechanism of action of NOV202 plus olaparib by immunohistochemistry analysis of collected tissue specimens, says Sereti. Expression of biomarkers, such as DNA repair, DNA damage, hypoxia, and stem cell markers, will be evaluated as part of the study, adds Sereti.
An additional study using a 50-gene mutational screening panel is ongoing to determine whether mutational status and PARP inhibitor sensitivity is correlated, concludes Sereti.